UCB's Global Corporate Website
Welcome to UCB in the United States
  • Healthcare Professionals
  • Patients
  • Investors

    • Categories

    Archives

    Nov

    19

    Positive Top-Line Results from Bimekizumab Phase 3 Psoriatic Arthritis Study Demonstrated Significant Improvements in Joint and Skin Symptoms

    Read More Share:linkedin| twitter| email

    Nov

    05

    UCB Showcases Key Rheumatology Data at ACR Convergence 2021

    Read More Share:linkedin| twitter| email

    Oct

    27

    Unique Patient-led and Co-authored Analysis of the Experience of Living with Myasthenia Gravis Published in Neurology and Therapy

    Read More Share:linkedin| twitter| email

    Oct

    20

    UCB to license its AI technology that improves identification of Osteoporosis to ImageBiopsy Lab

    Read More Share:linkedin| twitter| email

    Oct

    16

    Update on U.S. FDA Review of Biologics License Application (BLA) for bimekizumab

    Read More Share:linkedin| twitter| email

    Sep

    29

    New Bimekizumab Two-Year Data in Moderate to Severe Plaque Psoriasis Presented at the 30th European Academy of Dermatology and Venereology Congress

    Read More Share:linkedin| twitter| email

    Aug

    30

    UCB Announces BRIVIACT® (brivaracetam) CV Now FDA-Approved to Treat Partial-Onset Seizures in Pediatric Patients One Month of Age and Older

    Read More Share:linkedin| twitter| email

    Aug

    07

    New Two-Year Data Showed Bimekizumab Maintained High Levels of Skin Clearance in Patients with Moderate to Severe Plaque Psoriasis

    Read More Share:linkedin| twitter| email

    Apr

    28

    UCB Announces PDUFA Date for Bimekizumab

    Read More Share:linkedin| twitter| email

    Apr

    23

    "The New England Journal of Medicine" Publishes Results from Two Bimekizumab Phase 3 Studies in Moderate to Severe Plaque Psoriasis

    Read More Share:linkedin| twitter| email

    © 2009 - 2020 UCB, Inc., Atlanta. All rights reserved.
    USPR-CORP-0115-00003(2)